MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mineralys Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$20.92+0.62 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Mineralys Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.85B | $166.30M |
| Enterprise Value | $1.71B | $88.19M |
| PB Ratio | 3.36 | 2.03 |
| P/TBV Ratio | 3.36 | 2.29 |
Income (trailing twelve months)
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$370.79M | -$21.40M |
| Net Income | -$349.58M | -$22.46M |
| EBITDA | -$370.75M | -$16.91M |
| EPS (Diluted) | -$4.24 | -$0.83 |
Returns
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -80.9% | -53.2% |
| Return on Assets (ROA) | -69.7% | -40.9% |
| Return on Invested Capital (ROIC) | -93.8% | -32.4% |
| Return on Capital Employed (ROCE) | -57.2% | -38.1% |
Balance sheet
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $138.27M | $61.43M |
| Net Cash (Debt) | $138.27M | $15.35M |
| Net Cash Per Share | $1.56 | $0.66 |
| Equity (Book Value) | $550.92M | $49.09M |
| Book Value Per Share | $6.23 | $1.37 |
| Tangible Book Value | $550.92M | $23.52M |
| Working Capital | $646.48M | $76.81M |
Financial position
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 34.46 | 3.34 |
| Quick Ratio | 7.16 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$138.79M | -$12.35M |
Efficiency
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$4.60M | -$703.34K |
| Employee Count | 76 | 74 |
Dividends and yields
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -18.9% | -23.3% |
Shares
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 88,406,900 | 58,127,000 |
| Shares Change (YoY) | 46.2% | 10.9% |
| Shares Change (QoQ) | 7.15% | 0.54% |
| Float | 67,021,700 | 49,136,700 |
| Shares Held by Insiders | 24.2% | 11.6% |
| Shares Held by Institutions | 113.7% | 59.4% |
Scores
| Measure | Mineralys Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 7.27 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Mineralys Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.